Vor Biopharma Income Statement (2020-2026) | VOR

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter)
1.86M1.86M1.87M1.88M1.88M1.93M1.98M3.35M3.37M3.39M3.40M3.41M3.42M3.43M3.44M6.24M6.28M6.68M9.87M
Operating items
Research & Development (Quarter)
12.97M12.93M12.69M15.28M15.33M16.88M17.06M21.91M23.90M27.61M20.90M24.32M21.82M21.82M25.35M26.70M261.50M14.14M19.19M17.59M
Selling, General & Administrative (Quarter)
5.41M5.68M5.61M7.52M6.46M7.23M7.66M8.51M8.28M7.71M7.23M8.00M7.21M6.70M5.96M6.59M12.79M13.96M16.77M17.57M
Operating Expenses (Quarter)
18.38M18.60M18.31M22.80M21.79M24.10M24.73M30.42M32.17M35.32M28.12M32.33M29.04M28.51M31.31M33.29M274.28M28.11M35.96M35.16M
Operating Income (Quarter)
-18.38M-18.60M-18.31M-22.80M-21.79M-24.10M-24.73M-30.42M-32.17M-35.32M-28.12M-32.33M-29.04M-28.51M-31.31M-33.29M-274.28M-28.11M-35.96M-35.16M
EBIT (Quarter)
-18.38M-18.60M-18.31M-22.80M-21.79M-24.10M-24.73M-30.42M-32.17M-35.32M-28.12M-32.33M-29.04M-28.51M-31.31M-33.29M-274.28M-28.11M-35.96M-35.16M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.05M0.05M0.06M0.13M0.31M0.81M1.99M2.19M2.13M1.86M1.52M1.20M0.95M0.60M0.81M0.54M1.73M2.79M3.94M
Other Non Operating Income (Quarter)
4.15M0.00M
Non Operating Income (Quarter)
0.01M0.05M0.05M0.06M0.13M0.31M0.81M1.99M2.19M2.13M1.86M1.52M1.20M0.95M0.60M0.81M-1299.38M-784.58M1,758.82M-184.43M
Net income details
EBT (Quarter)
-19.07M-19.25M-18.97M-23.46M-22.98M-24.97M-26.63M-29.98M-30.43M-33.47M-28.66M-32.44M-27.91M-29.21M-32.40M-34.17M-283.94M-26.41M-33.27M-31.34M
Profit After Tax (Quarter)
-18.37M-18.55M-18.25M-22.74M-21.66M-23.79M-23.91M-28.43M-29.98M-33.19M92.30M-0.01M0.02M-27.42M86.16M-32.49M-1573.67M-812.69M-695.95M-0.75M
Income from Non-Controlling Interests (Quarter)
-1.07M-0.25M0.15M0.41M0.60M-0.26M0.16M0.20M-0.01M0.02M0.14M-0.05M0.00M-0.01M-0.00M0.03M-0.75M
Income from Continuing Operations (Quarter)
-19.07M-19.25M-18.97M-23.46M-22.98M-24.97M-26.63M-29.98M-30.43M-33.47M-28.66M-32.44M-27.91M-29.21M-32.40M-34.17M-283.94M-26.41M-33.27M-31.34M
Consolidated Net Income (Quarter)
-19.07M-19.25M-18.97M-23.46M-22.98M-24.97M-26.63M-29.98M-30.43M-33.47M-28.66M-32.44M-27.91M-29.21M-32.40M-34.17M-283.94M-26.41M-33.27M-31.34M
Income towards Parent Company (Quarter)
-19.07M-19.25M-18.97M-23.46M-22.98M-24.97M-26.63M-29.98M-30.43M-33.47M-28.66M-32.44M-27.91M-29.21M-32.40M-34.17M-283.94M-26.41M-33.27M-31.34M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-18.37M-18.55M-18.25M-22.74M-21.66M-23.79M-23.91M-28.43M-29.98M-33.19M-26.26M-30.80M-27.84M-27.56M-32.40M-32.49M-1573.67M-812.68M-33.27M-31.34M
Additional items
EPS (Basic) (Quarter)
-9.97-10.05-10.92-12.19-11.57-12.52-12.09-8.58-8.94-9.82-7.82-9.06-8.15-8.05-9.43-5.21-251.24-121.63-3.37-0.73
EPS (Diluted) (Quarter)
-9.97-10.05-10.92-12.19-11.57-12.52-12.09-8.58-8.94-9.82-7.82-9.06-8.15-8.05-9.43-5.21-251.24-121.63-3.37-0.73
Shares Outstanding (Quarter)
1.84M1.85M1.67M1.86M1.87M1.90M1.98M3.31M3.35M3.38M3.36M3.40M3.41M3.42M3.44M6.24M6.26M6.68M9.87M43.01M
Shares Outstanding (Diluted) (Quarter)
1.84M1.85M1.67M1.86M1.87M1.90M1.98M3.31M3.35M3.38M3.36M3.40M3.41M3.42M3.44M6.24M6.26M6.68M9.87M43.01M
EBITDA (Quarter)
-18.38M-18.60M-18.31M-22.80M-21.79M-24.10M-24.73M-30.42M-32.17M-35.32M-28.12M-32.33M-29.04M-28.51M-31.31M-33.29M-274.28M-28.11M-35.96M-35.16M
Interest Expenses (Quarter)
0.70M0.70M0.72M0.73M1.33M1.18M2.72M1.54M0.45M0.28M2.40M1.64M0.07M1.65M1.69M1.69M10.20M0.04M0.11M0.11M